Immutep to discontinue TACTI-004 Phase III study in first line NSCLC

Corroborated by 1 source from 1 publisher

globalscience5d ago

TL;DR

According to investing.com, immutep to discontinue TACTI-004 Phase III study in first line NSCLC.

Investing.com News

https://www.investing.com/news/sec-filings/immutep-to-discontinue-tacti004-phase-iii-study-in-first-line-nsclc-93CH-4562025